Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Foralumab Safety and Modulation of Microglial Activation Evaluated by PET Imaging in Patients With Early Symptomatic Alzheimer's Disease

NCT06489548 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT06489548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06489548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Foralumab Safety and Modulation of Microglial Activation Evaluated by PET Imaging in Patients With Early Symptomatic Alzheimer's Disease
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 16, 2025
Completion date
December 31, 2026
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimers disease, dementia, mild cognitive impairment due to alzheimer's disease